Celladon plans venture financing now Mydicar is on fast track
This article was originally published in Scrip
Executive Summary
Following the news this week that its gene therapy for advanced heart failure has been granted fast track designation by the US FDA, Celladon is finalising a venture financing to take the company into the next stage of development, CEO Dr Krisztina Zsebo told Scrip.